

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
<b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	<b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> April 26, 2017	
<b>Re.:</b> Press Release	

Dear Sir / Madam,


We enclose herewith a copy of press release dated April 26, 2017, titled Zydus receives final approval from the USFDA for Cholestyramine for Oral Suspension USP.


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **Cadila Healthcare Limited**

  
**Open H. Shah**  
**Company Secretary**



Encl.: As above

## **Zydus receives final approval from the USFDA for Cholestyramine for Oral Suspension USP**

*Ahmedabad, 26 April 2017*

Zydus Cadila has received the final approval from the USFDA to market Cholestyramine for Oral Suspension USP, 4 grams per scoopful.

It is indicated as an adjunctive therapy to the diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*